Pharma’s New Patient Access Website: A Signal for Insurers?
PhRMA introduces an online platform connecting patients with discounted pharmaceuticals as the U.S. government pressures drug companies to reform pricing and distribution.
U.S. Prospective MFN Pricing Could Balance Drug Costs and Innovation
Explore how the U.S. prospective most-favored-nation (MFN) pricing strategy aims to lower drug prices while preserving pharmaceutical innovation and encouraging fair global contributions to R&D funding.
CMS Proposes 2027 Medicare Advantage Rule; Drug Price Negotiations Advance
Summary of recent CMS proposals affecting 2027 Medicare Advantage and Part D, plus updates on Medicare drug price negotiations impacting federal health programs.
Medicare Drug Price Negotiations Yield $12 Billion Savings on 15 Key Medications
New Medicare drug price negotiations under the Inflation Reduction Act cut costs for 15 major medications, saving Medicare $12 billion annually.
Medicare Drug Price Negotiations Cut Costs for 15 Key Medications
New Medicare drug price negotiations reduce government costs on 15 high-spend medications, including cancer and diabetes treatments, saving $12 billion annually.
Trump Administration Secures Medicare Drug Price Cuts for 15 Medications
The Trump administration finalizes agreements reducing Medicare prices for 15 drugs, aiming to save billions and impact Medicare Part D plans and drug affordability policies.
Pharma Firms Slash Medicare Drug Prices in Trump Administration Deal
Pharmaceutical companies agree to significant Medicare drug price cuts under Trump administration, projecting billions in savings with impacts on Medicare Part D and drug affordability.
CMS Launches Voluntary Medicaid MFN Drug Pricing Model; Trump-Era Manufacturer Agreements Expand
CMS unveils the GENERous Medicaid payment model introducing MFN drug pricing, alongside expanded Trump administration drug pricing agreements and key regulatory updates for 2026.
Novo Nordisk, Eli Lilly Cut GLP-1 Prices for Expanded Medicare Market Access
Novo Nordisk and Eli Lilly agree to lower GLP-1 drug prices in exchange for expanded Medicare and Medicaid coverage, marking a major shift in U.S. drug pricing and access.
Impact of MFN Drug Pricing Policy on Medicare Part D Deadline Approaches
The looming deadline for drugmakers to comply with the Most Favored Nation drug pricing policy raises concerns over potential disruptions to Medicare Part D, highlighting regulatory and market risks for U.S. drug pricing and federal entitlement programs.